CorePharma: Innovation Through Investment and Collaboration

CorePharma specializes in difficult-to-develop, high-value products across a variety of therapeutic areas and currently produces almost one-half billion tablets and capsules annually. Our expertise in product development and manufacturing is complemented by robust sales, marketing, and distribution capabilities.

CorePharma currently operates 4 state-of-the-art facilities, totaling 115,000 square feet of space, in Middlesex, New Jersey. These facilities accommodate all research and development, manufacturing, packaging, and warehousing activities carried out by more than 300 employees. The facilities are FDA-registered and licensed to manufacture and distribute controlled substances from C-II through C-V. We continually invest in manufacturing, packaging, and testing facilities to improve efficiencies, ensure quality, add capacity, and enhance technologies. Our commitment to investing in the future is unwavering.

CorePharma’s ever-expanding manufacturing capabilities currently include:

• Tablets
• Hard-shell gelatin capsules with the capability to bead fill, with batch sizes ranging up to 600 kg
• Low-shear and high-shear granulations
• Direct compression blends
• Functional and nonfunctional aqueous film coatings

CorePharma has the ability to fill, label, and package solid-dose tablets and capsules; additionally, we have established relationships with vendors who specialize in micronization, blister packaging, and powder filling. Leveraging these external partnerships, we manufacture solvent-based products using a variety of technologies. In addition, these relationships permit us to handle highly potent compounds or compounds that require containment.

The CorePharma Research & Development Center is located in a newly constructed building within the CorePharma campus in Middlesex, New Jersey. This multifunctional facility boasts the latest in analytical equipment and, most importantly, more than 30 professionals with decades of experience. Our 6 processing rooms are equipped to develop oral tablet, capsule, and pellet dosages and are outfitted with negative pressure to prevent crosscontamination. Our team is experienced in handling and developing controlled substances, including Schedule II, III, IV, and V drugs.

The latest addition to the CorePharma Research & Development center is an innovative analytical development research lab housing basic laboratory equipment, as well as 20 HPLC systems (with photodiode array and refractive index detector), including UPLC and LCMS systems running with data acquisition software from Totalchrom™ and Empower. The laboratory contains automated and manual dissolution apparatus 1 and 2, and GC with both direct and head space analysis.

CorePharma is dedicated to effectively growing our business through sound product selection and collaborative partnerships. In addition to our own internal product development, we welcome collaboration with companies that have a culture of quality, value a supportive environment, and whose goals align with those of CorePharma. Our Business Development team recognizes the importance of partnerships with businesses in all phases of development, ranging from exclusive API arrangements and product development agreements to marketing licenses.

In 2005, RoundTable Healthcare Partners LLP, a leading global private equity firm, acquired a majority share of CorePharma.

For more information, visit www.corepharma.com.